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Since the efficacy of mycophenolate mofetil (MMF) to
treat immunoglobulin A (IgA) nephropathy is controversial,
we extended our original study by following 40 Chinese
patients with established IgA nephropathy for 6 years.
All patients were maintained on their angiotensin blockade
medication and half were randomized to receive MMF
for 6 months. After 6 years, 11 patients required dialysis
(2 from the MMF and 9 from the control group). Significantly,
only 3 treated (as compared to 10 control) patients reached
the composite end point of serum creatinine doubling
or end-stage renal disease. Linear regression showed the
annualized decline in the estimated glomerular filtration
rate was significantly less in the MMF-treated group.
Urinary protein excretion and the albumin-to-creatinine ratio
were lower with MMF treatment during the first 24 months,
beyond which there was no difference between groups.
Multivariable Cox regression analysis showed that the
baseline estimated glomerular filtration rate and proteinuria,
and change in the urine albumin-to-creatinine ratio at 1 year
to be important predictors of progression to end-stage renal
disease. We found that among Chinese patients with IgA
nephropathy who had mild histologic lesions and persistent
proteinuria despite maximal angiotensin blockade, MMF
treatment may result in transient and partial remission
of proteinuria in the short-term and renoprotection in
the long-term.
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To date, there is no specific treatment available for
immunoglobulin A nephropathy (IgAN), which remains
the most common primary glomerulonephritis worldwide.1
The predominant glomerular deposition of abnormally
glycosylated polymeric IgA2 suggests a pathogenetic role for
deranged IgA synthesis. The recent discovery of the
involvement of the ubiquitin–proteasome pathway in IgAN
further supports an immune-mediated pathogenetic link in
this disorder.3 Mycophenolate mofetil (MMF) is a potent
immunosuppressive agent which is relatively selective for
lymphocytes and inhibits antibody production by B cells
more than any other immunosuppressants.4 Besides, case
series suggest that MMF may be effective in reducing
proteinuria in a variety of glomerular diseases, including
IgAN.5,6 So far, few randomized controlled trails have studied
the role of MMF in patients with IgAN.
We have previously reported the short-term (up to 18
months) antiproteinuric effect of MMF administered
for 24 weeks in a selected group of IgAN patients, namely
those with persistent proteinuria despite angiotensin
blockade and relatively preserved renal function and
histologically mild lesions.7 The rationale of using MMF
for 24 weeks in our original study was to balance the
envisaged benefits of suppressing aberrant IgA synthesis
without exposing the patient to the potential side effects of
prolonged immunosuppression. Conversely, several other
randomized controlled trails have produced conflicting
results on the efficacy of MMF in IgAN.8–10 However, there
has been no report on the long-term renoprotective potential
of MMF treatment in IgAN. In this study, we report the
results of an extended 6-year follow-up of our original
randomized cohort of IgAN subjects who had persistent
proteinuria despite adequate angiotensin blockade using
either angiotensin-converting enzyme inhibitor (ACEi) or
angiotensin II antagonist.
RESULTS
Baseline characteristics
The flow diagram depicting the patient enrolment process
was previously reported.7 The baseline demographic and
clinical characteristics as well as histological grading of renal
biopsies, also reported previously,7 were similar between the
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two groups (Table 1). In particular, all recruited subjects had
persistent proteinuria more than 1 g/24 h despite adequate
angiotensin blockade.
Patient and renal survival
All group 1 patients completed the planned 6 months of
MMF treatment, and all patients in both groups were
followed for at least 6 years since randomization. All patients
were alive at the end of the follow-up. Eleven patients
(27.5%) developed end-stage renal disease (ESRD) in this
cohort over the 6-year follow-up. Two (10%) patients in the
MMF group and nine (45%) patients in the control group
developed progressive renal failure that required dialysis
(Figure 1). Ten of these 11 patients were commenced on
peritoneal dialysis, and 1 patient in the control group
underwent pre-emptive renal transplantation. The 6-year
renal survival was therefore 90% in MMF-treated patients
and 55% in control subjects (P¼ 0.015). In addition, one
patient in each group had doubling of serum creatinine not
reaching end-stage renal failure by the end of 6 years
(Figure 2).
Urine protein excretion
Our previous report7 suggested a modest (30% reduction
from baseline) but significant difference in urine protein
excretion in favor of the MMF group over the initial
18-month follow-up period. Extended follow-up showed
that such inter-group difference persisted through 24 months
of follow-up. However, beyond 24 through 72 months, this
between-group difference in proteinuria was lost. In our
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Figure 1 |Kaplan–Meier analysis of overall renal survival
of 40 IgAN subjects over the 6-year follow-up period.
Ctl, control; MMF, mycophenolate mofetil.
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Figure 2 |Kaplan–Meier analysis of the likelihood of not
reaching the primary composite end point of doubling of
serum creatinine, dialysis, or death of 40 IgAN subjects over
the 6-year follow-up period.
Table 1 | Baseline clinical and histological characteristics of
study subjectsa
Characteristic
Group 1
(n=20)
Group 2
(n=20)
Clinical parameter
Age (years) 42.1±2.6 43.3±2.8
Male/female 6:14 8:12
Number of antihypertensive drugs 1.4±0.2 1.7±0.2
On ACEi/on ARB 16:4 14:6
Lisinopril (dose in mg/day) 10 (16±3.9) 9 (14.2±5.0)
Enalapril (dose in mg/day) 6 (14.2±4.9) 5 (13±6.7)
Losartan (dose in mg/day) 4 (87.5±25) 6 (83.3±25.8)
Diltiazem (dose in mg/day) 6 (95±44.2) 8 (127.5±57.3)
Atenolol (dose in mg/day) 2 (50 each) 3 (75±25)
Blood pressure (mmHg)
Systolic 120±3.2 122±3.2
Diastolic 74±2.2 71±2.6
Estimated GFR (ml/min per
1.73m2 BSA)b
52.5±4.40 50.0±4.51
Urine protein excretion (g/24 h) 1.8±0.21 1.87±0.28
Urine albumin-to-creatinine ratio
(mg/mmol)
123±18 127±20
Histological grading
Morphological score distributionc
Grade II 5 7
Grade III 11 11
Grade IV 4 2
Prognostic score distributiond
Glomerular grading (GG)
GG 1 14 15
GG 2 6 5
GG 3 0 0
Tubulointerstitial grading (TIG)
TIG 1 13 11
TIG 2 7 9
TIG 3 0 0
Hyaline arteriolosclerosis (HA)
Absent 16 15
Present 4 5
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; BSA, body surface area. P40.05 for all comparisons between the
two groups.
aPlus-minus values are means±s.e. P40.05 for all comparisons between the two
groups.
bUsing the abbreviated 4-variable Modification of Diet in Renal Disease study equation.28
cDetermined in accordance with the classification by Haas,26 taking into account the
degree of mesangial proliferation, glomerular sclerosis, and tubular atrophy, on a scale of
1–5. Grade 1 indicates minimal histological changes, whereas grade 5 indicates advanced
sclerosis and cortical tubular loss.
dDetermined in accordance with the grading by To et al.27 GG 1, mean sclerosis per
glomerulus, 0 too25%; GG 2, 25 too50%; and GG 3,X50%. TIG 1, tubular atrophy and
interstitial fibrosis were absent or in an areao5%; TIG 2, 5 too50%; and TIG 3,X50%.
HA was defined as the presence of arteriolar hyaline or proteinaceous exudation, with or
without smooth muscle hyperplasia or luminal reduction.
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mixed model incorporating group, visit, and the interaction
between these two factors, the overall urine protein excretion
rate over the study period was not significantly better among
MMF-treated versus control subjects (Figure 3a). Similarly,
the urine albumin-to-creatinine ratios demonstrated the
same trend (Figure 3b).
Changes in eGFR and blood pressure
The rate of estimated glomerular filtration rate (eGFR)
decline over the entire follow-up duration obtained by linear
regression for each patient was annualized and presented in
Figure 4a. Although there was no demonstrable difference in
renal function during the initial 18 months of follow-up,7
there was a significantly more rapid eGFR decline in control
subjects versus MMF-treated patients when the observation
period was extended to 6 years. However, when the slope of
eGFR decline was re-classified according to the type of
angiotensin blockade that was given, there was no significant
difference between groups (Figure 4b).
All subjects achieved target blood pressure control
throughout follow-up, and there was no significant difference
in systolic and diastolic blood pressures (Figure 5). The
antihypertensive drugs at last clinic visit are listed in Table 2.
Predictive factors for progression to ESRD
The reduction of proteinuria at 6 months correlated
significantly with the slope of eGFR against time (Figure 6).
Using multivariable Cox regression analyses, baseline eGFR
and change of urine albumin-to-creatinine ratio at 1-year
post-randomization were predictive of ESRD or the compo-
site end point of doubling of serum creatinine and ESRD
independent of age, gender, blood pressure, and histological
score (Table 3).
Adverse events
Mycophenolate mofetil was well tolerated. None of the
patients required drug discontinuation. During MMF treat-
ment, three patients developed a decrease in hemoglobin
level to below 10 g/dl that improved after dose adjustment.
One patient developed diarrhea, and another reported
transient upper gastrointestinal upset. Three infective epi-
sodes (two of urinary tract infection, and one of cervical
lymphadenitis) occurred in two MMF-treated patients, and
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Figure 3 |Proteinuria change from baseline to study end.
(a) Changes in urinary protein excretion during follow-up.
The geometric mean values, with 95% confidence intervals,
are shown. *P¼ 0.019, wP¼ 0.023, zP¼ 0.007 versus the control
group at the corresponding time point. (b) Changes in urinary
albumin-to-creatinine ratio during follow-up. The geometric
mean values, with 95% confidence intervals, are shown.
*P¼ 0.019, wP¼ 0.006, zP¼ 0.027 versus the control group
at the corresponding time point.
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Figure 4 |Annual change in estimated GFR. (a) The rates of
change in eGFR over the study period were calculated for each
patient by linear regression analysis. The median change in eGFR,
indicted by the horizontal line, was 1.125ml/min per 1.73m2 per
year in the MMF group and 3.812ml/min per 1.73m2 per year in
the control group (P¼ 0.021). (b) The annualized rates of change
in eGFR over the study period according to the type of
angiotensin blockade given: ACEi (open circle), ARB (half-filled
circle), and combination (solid circle).
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all responded to simple oral antibiotic treatment. No further
adverse event was documented during the study after
completion of MMF in the treatment group, and there was
no adverse events in control patients throughout the
observation period.
DISCUSSION
The use of MMF for the treatment of IgAN has been a matter
of controversy in recent years. The first promising study was
published in 2002 by Chen et al.8 who showed that MMF
administered for 12 months was more effective than
corticosteroid therapy in reducing proteinuria among 62
IgAN subjects with urinary protein excretion exceeding 2 g/24h.
However, a subsequent Belgian study failed to reproduce
these beneficial effects of MMF treatment. Maes et al.9
reported in 2004 that MMF conferred no therapeutic benefit
in 21 patients versus 13 patients administered placebo for 3
years. In this study, these investigators included only patients
with histologically unfavorable criteria, hypertension, and
stage 2–4 chronic kidney disease (inulin clearance 21–69ml/
min), whereas those with mild histopathological changes but
heavy proteinuria were excluded. Another study from the
United States reported no benefit of MMF administered for 1
year as a ‘salvage’ therapy in 16 patients with advanced renal
insufficiency.10 In 2005, we reported that MMF was effective
in reducing proteinuria by about 30% from baseline among
40 subjects with histological mild lesions and persistent
proteinuria exceeding 1 g/24 h despite maximal angiotensin
blockade.7 A recent meta-analysis11 of these trials that yielded
conflicting results concluded that MMF cannot be recom-
mended for routine use in treating IgAN. However, all these
clinical trials examined short-term outcome parameters such
as proteinuria and the rate of change of GFR or serum
creatinine, and long-term hard outcome follow-up data, such
as renal and patient survival, are lacking. This is particularly
important in IgAN that typically runs a slowly progressive
and indolent course that lasts over 20–30 years.
In this study, we report the 6-year outcome in our original
cohort of 40 IgAN subjects who underwent randomization.
First, there was a clear renal survival advantage in patients
who received MMF. The rate of eGFR decline was also lower
in the MMF group over the follow-up period. Conversely, the
rate of renal progression in the control group appeared faster
than that would be expected for ARB-treated patients. This is
not unexpected, as we only recruited subjects with persistent
proteinuria over 1 g/24 h despite angiotensin blockade, which
suggests that patients in whom proteinuria is resistant to
angiotensin blockade may have a less-favorable prognosis.
One explanation for these observations may be related to the
Table 2 | Antihypertensive drugs at last follow-up
MMF group Control group
Total number of drugs 1.95±0.18 1.85±0.22
ACEi without ARB 4 9
ARB without ACEi 5 7
ACEi plus ARB 10 4
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; MMF, mycophenolate mofetil.
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Figure 6 |Pearson’s correlation between reduction in urinary
protein excretion at 6 months and the slope of eGFR over
time.
Table 3 |Multivariate analysis for the effect of baseline risk markers and for treatment-induced change in these markers
End point Multivariate risk marker Hazard ratio 95% CI P-value
Renala Baseline eGFR (ml/min per 1.73m2) 0.92 0.88–0.97 0.001
Urine ACR change at 1 year (g/g) 5.42 1.94–15.20 0.001
Reduction of urine ACR (g/g) 0.18 0.07–0.52 0.001
ESRD Baseline eGFR (ml/min per 1.73m2) 0.91 0.86–0.96 0.001
Urine ACR change at 1 year (g/g) 7.65 2.17–26.9 0.002
Reduction of urine ACR (g/g) 0.13 0.04–0.46 0.002
Abbreviations: ACR, albumin-to-creatinine ratio (each g/g equals 113mg/mmol); ESRD, end-stage renal disease.
aComposite renal end point of ESRD or doubling of serum creatinine
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Figure 5 |Changes in systolic and diastolic blood pressure.
Between-group differences for both systolic and diastolic
blood pressures were not statistically significant at each
time point.
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reduction of proteinuria. In our earlier study, we demon-
strated a 30% reduction of proteinuria from baseline at 18
months in MMF-treated subjects. On extended follow-up
here, the inter-group difference persisted till 24 months.
Thereafter, this difference in proteinuria and urine albumin-
to-creatinine ratio was no longer apparent between MMF-
treated and control subjects. Nonetheless, even a transient
and incomplete reduction of proteinuria may be important
for renoprotection, as in vitro and clinical studies have
repeatedly demonstrated the deleterious effects of persistent
glomerular proteinuria. For instance, we and others have
shown that abnormal protein trafficking may cause renal
injury through the induction in renal tubular cells of
proinflammatory and profibrotic cytokines, notably comple-
ment C3, MCP-1, IL-8, fibronectin, macrophage migration
inhibitory factor,12–16 and transforming growth factor-b
and its surface receptor.17,18 These cytokines may in turn
stimulate interstitial leukocyte infiltration, inflammation,
and ultimately, scarring and loss of renal function.
Clinically, major multi-centered trials, such as the post hoc
analyses of the RENAAL19 and REIN20 trials, have confirmed
that reduction of albuminuria during the first 6 months of
antiproteinuric treatment was associated with a reduced rate
of GFR decline and risk of developing renal end point
(ESRD) during long-term follow-up in diabetic and non-
diabetic subjects, respectively. Reduction of proteinuria by
X30% at 6 months was a favorable determinant of renal
outcome (with significantly reduced hazard ratios for
doubling of serum creatinine and ESRD) at 4 years in
diabetic nephropathy.19 Furthermore, partial remission of
proteinuria has been shown to be a positive prognostic
indicator in idiopathic membranous nephropathy.21 In this
study, we showed a weak, albeit statistically significant,
correlation between proteinuria reduction at 6 months and
the slope of eGFR over time. Although this is in agreement
with the post hoc analysis results of RENAAL19 and REIN,20 a
larger cohort of study subjects is required to validate this
notion in MMF-treated IgAN patients. In addition, we
showed that the change in albuminuria at 1 year is strongly
predictive of doubling of serum creatinine and ESRD. Our
multivariable Cox regression model also showed that baseline
eGFR and reduction of proteinuria on follow-up were also
important predictors of subsequent renal failure, which is
in keeping with prevailing data. However, histological grade
and use of MMF was removed in the multivariate model,
which might be related to the small patient number.
Why do Chinese and Caucasian patients have different
responses to MMF treatment? Floege22 suggested race, dose
of MMF, and ACEis used might account for the differences. It
must be emphasized also that in the Belgian study,9 patients
with mild histopathological changes but heavy proteinuria
were excluded, which were exactly the inclusion criteria in
our study. Noting the potential immunosuppressive profile of
MMF, we did not want to include patients with histologically
unfavorable lesions who might have been destined to
progress no matter what, which probably happened in the
study by Frisch et al.10 At the same time, we wished to include
subjects who were at risk of progression, namely, those with
persistent proteinuria despite the best available antiproteinu-
ric therapy at the time of study inception. Therefore, there
appears to be a fundamental difference in patient character-
istics between the Caucasian studies and the present cohort.
There are, however, several limitations of our results. First,
the patient number was small to start with. This was related
to the off-label use of MMF that limited our research Ethics
Committee to approve the trial on a much larger scale, and
the relatively high cost of the drug at the inception of the
study. Nevertheless, our initial power analysis suggested that
40 subjects would have been sufficient to achieve 80% power
had there been a 50% difference in the final urine protein
excretion rate between MMF-treated and control subjects.7
Although there was an overall reduction of proteinuria at 18
months’ follow-up, not all patients responded in the same
manner and rebound was evident after treatment cessation in
some subjects on extended observation. Therefore, our small
study population provides only level B evidence for the
efficacy of MMF in IgAN. Larger trials are needed to yield a
more definitive trend of proteinuria responses. Although the
baseline characteristics were statistically similar between
MMF and control groups, the randomization process
resulted in a slightly higher baseline proteinuria and lower
eGFR in the control group. It is possible that such subtle
initial differences may be exaggerated over long periods of
observation. In addition, more patients in the MMF group
received combined ACEi/ARB therapy, which may have
contributed to the better outcome in this group, given the
antifibrotic activity of ACEi/ARB combination beyond its
blood pressure and proteinuria lowering effects.23 Although
subgroup analysis by the type of angiotensin blockade did
not reveal such a contention, the small patient number in
each group cannot confidently exclude a type II statistical
error. Finally, our results only apply to patients in whom
proteinuria is not controlled despite adequate angiotensin
blockade. Randomized controlled trails that include large
numbers of patients of different ethnic groups are in need to
answer these questions. We eagerly await the results of the
North American24 and Italian25 trials.
PATIENTS AND METHODS
Study design and participants
Our original prospective, randomized controlled trial that com-
menced in year 2001–2002 has recruited 40 subjects with IgAN from
two major regional renal centers in Hong Kong. The study was
approved by an Institutional Review Board and Ethics Committee of
the Hong Kong Hospital Authority, and all participating patients
gave written informed consent. Patients were randomly assigned by
drawing envelopes to one of two treatment groups in an open-label
manner: MMF or control group.
Patients of either gender were eligible if they had histologically
confirmed IgAN and clinically significant proteinuria of over 1 g/
24 h on 3 or more consecutive measurements 4–6 weeks apart,
despite adequate blockade of the angiotensin system using an ACEi
or angiotensin II receptor blocker for at least 6 months to achieve a
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target blood pressure of o125/85mmHg. Eligible subjects were
randomly assigned to receive MMF (2 g/day if body weight was
X60 kg, or 1.5 g/day if body weight was o60 kg) for 6 months in
addition to concurrent medications, or to continue contempora-
neous medications without addition of MMF. Blood pressures were
recorded as the mean of three morning measurements (to the
nearest 2mmHg). Additional antihypertensive drugs were allowed
to achieve blood pressure target. Patients with glomerulopathies
other than IgAN, serum creatinine over 300mmol/l (3.4mg/dl),
systemic infection or malignancy, and women of childbearing age
who were pregnant, lactating, or unwilling to practice reliable
contraception, were excluded.
Histological assessment
The histological diagnosis of IgAN was based upon the demonstration
of mesangioproliferative changes on light microscopy and the
concomitant presence of predominant or codominant mesangial
deposition of IgA. Histological grading of all renal biopsy samples were
determined by a central pathologist in accordance with the classification
published by Haas.26 Patients with minimal or no mesangial
hypercellularity (Haas subclass 1) or advanced glomerulosclerosis and
tubular atrophy (Haas subclass 5) were excluded. To provide
information on prognosis, the biopsy samples were also graded with
respect to the extent of glomerular sclerosis, tubular loss, interstitial
fibrosis, and hyaline arteriolosclerosis, in accordance with the method
developed by To et al.,27 who showed that glomerular sclerosis
represented the most important prognostic factor in adult patients
with primary IgAN and had a strong predictive value for renal survival.
Patient follow-up
On study entry in 2002, full medical histories and physical findings
were documented. Baseline investigations included full blood count,
liver and renal biochemistries, 24-h urine protein excretion, urinary
albumin-to-creatinine ratio, creatinine clearance rate, serum IgA
level, and plasma lipid profile. At each clinic visit, blood pressure,
body weight, blood count, renal function, 24-h urine protein,
urinary albumin-to-creatinine ratio, and creatinine clearance were
monitored. To reduce variability, all assays were performed at a
single central laboratory using standard methods. After 6 months,
MMF was discontinued in the treatment group. The entire study
duration for both groups of patients was 6 years.
Study end points
The primary composite outcome for between-group comparison
was renal survival. ESRD was defined as the need to start dialysis or
undergo kidney transplantation. Secondary outcomes included
changes in urinary protein excretion rate and albumin-to-creatinine
ratio, and the composite end point of doubling of baseline serum
creatinine, end-stage renal failure, or death.
Statistical analysis
Data are presented as means±s.e. The main efficacy analysis was
performed on an intention-to-treat basis and included all patients
who underwent randomization. Continuous characteristics at the
start of treatment were compared with Wilcoxon rank-sum tests.
Categorical groups were compared by w2-test and Fisher’s exact test,
as appropriate. Differences between study entry and study end in
each group were tested by Wilcoxon signed rank test. Cumulative
renal survival was calculated with the Kaplan–Meier method, and
comparisons between groups were performed with the log-rank test.
As albuminuria shows a skewed distribution in this study, averages
were expressed as geometric mean. Changes in the log-transformed
urinary protein excretion rate and albumin-to-creatinine ratio from
baseline to months 6, 12, 18, 24, 36, 48, 60, and 72 (end point) were
assessed for each time point with the Mann–Whitney U-test to detect
inter-group differences. Treatment comparisons between the patients
who did and did not receive MMF were performed with the use of a
two-sided test with a significance level of 0.05. Least squares mean
differences between the groups for the change from baseline in the
urinary albumin-to-creatinine ratio (and associated 95% confidence
intervals) were back-transformed to provide meaningful values. In addi-
tion, a mixed-effects model with the use of the appropriate procedure
of the Statistical Package for the Social Sciences Inc., Chicago, IL, USA
(Linear Mixed Model) was implemented to detect differences in protein-
uria over time. The model included study group, visit, and the interaction
term for these two factors, as well as baseline urinary albumin-to-
creatinine ratio, as fixed effects and visits as repeated measurements.
Estimated glomerular filtration rate was calculated using the
abbreviated 4-variable MDRD study equation, where
eGFR¼ 186.3 (serum creatinine, mg/dl)1.154 (age upon follow-
up, years)0.203 (0.742 for female) 1.21 for black race.28 The rates of
change in eGFR (slope of eGFR vs time plot) over the study period were
calculated for each patient by linear regression analysis. The slope for
patients who developed ESRD requiring renal replacement therapy was
computed to the time point when such therapy was initiated. Inter-
group differences were compared using non-parametric Mann–Whitney
U-test. Correlation between proteinuria reduction at 6 months and the
slope of eGFR over time was computed using Pearson’s method. A two-
tailed P-value of less than 0.05 was taken as the level of significance.
Factors predictive of renal failure and were identified with Cox
regression analysis. Factors with Po0.25 on univariate analysis were
entered into the multivariable Cox regression model. A backward
elimination procedure with P40.05 to remove was performed to
identify independent predictors for the development of ESRD. To
identify risk factors at baseline and treatment-induced changes in
risk factors at 1 year that were independent predictors of the renal
end points, baseline and baseline and change at 1-year multivariate
Cox models were performed. Baseline risk factors were selected among
the following covariates: age, gender, mean arterial blood pressure
(diastolic blood pressureþ 0.333 pulse pressure), eGFR, and urine
albumin-to-creatinine ratio, and histologic grade using Haas classifica-
tion. Risk factor for treatment-induced change analysis was change
in urine albumin-to-creatinine ratio at 1-year postrandomization.
All statistical analyses were performed using SPSS v.16.0 or GraphPad
(GraphPad Software Inc., La Jolla, CA, USA) Prism v.5.0 as appropriate.
This trial is registered at ClinicalTrials.gov with the number
NCT00863252.
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